DH has put in place a pharmacovigilance system for COVID-19 immunization, including receiving reports of Adverse Events Following Immunization (“AEFIs”) related to the COVID-19 vaccines used in Hong Kong from healthcare professionals and pharmaceutical industries.
Pursuant to the requirements of the Prevention and Control of Disease (Use of Vaccines) Regulation, Cap. 599K to monitor any adverse event that occurs to the recipient associated with the administration of the relevant vaccine, the Director of Health appointed the Expert Committee on Clinical Events Assessment Following COVID-19 Immunization (“Expert Committee”) to provide independent assessment of potential causal link between AEFIs and COVID-19 vaccines used in Hong Kong and to provide expert advice to the Government on safety-related matters. The Department of Health also partners with the University of Hong Kong to conduct an active surveillance programme for Adverse Events of Special Interest (“AESIs”) related to COVID-19 vaccines.
Thematic webpage:
https://www.covidvaccine.gov.hk/en/vaccine
Report on the Safety Monitoring of COVID-19 Vaccines in Hong Kong (updated regularly):
https://www.drugoffice.gov.hk/eps/do/en/doc/Safety_Monitoring_of_COVID-19_Vaccines_in_Hong_Kong.pdf
3. Multilingual information
To facilitate more ethnic minorities to receive the Government’s latest information, various materials on COVID-19 vaccine safety monitoring and fact sheets etc. have been translated into multiple languages. For details, please refer to the attachment.
We would like to solicit your support to disseminate the information to your colleagues, work associates and/or business partners so that they could adopt proper preventive measures. Thank you very much for your support.
Department of Health